MULTIPLE MYELOMA

Promising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma.

Results from CC-220-MM-001 trial support further research of iberdomide-based regimens in multiple myeloma that investigators hope will lead to phase 3 randomized trials and eventual FDA approval of iberdomide in these combinations.

Krina K. Patel, MD, MSc, discusses how she chooses treatment for her patients with early or late relapsed/refractory multiple myeloma.

Considerations for future unmet needs and novel therapies in multiple myeloma, followed by practical advice for community oncologists.

In the context of multiple myeloma, Peter Voorhees, MD, considers the role of doublet vs triplet therapy, initial therapy selection, and monitoring treatment response.

Peter Voorhees, MD, reflects on practical implications of the MAIA trial and how best to manage a patient with newly diagnosed multiple myeloma.

Updated results from the MAIA trial, which tested the addition of daratumumab to lenalidomide-dexamethasone therapy in patients with transplant-ineligible newly diagnosed multiple myeloma.

Expert insight on the optimal management of transplant-ineligible newly diagnosed multiple myeloma in light of available therapies and clinical data.

Peter Voorhees, MD, provides a broad overview on risk assessment and the goals of therapy in multiple myeloma management.

According to phase 1 data from the MagnetisMM-1 trial, elranatamab may be a good treatment option for patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology Case-Base Roundtable event, Andrzej Jakubowiak, MD, PhD, led a discussion on new agents for the treatment of multiple myeloma.

In the MagnetisMM-1 study, elranatamab induces response with tolerable safety in patients with relapsed or refractory multiple myeloma.

Two year after being diagnosed with stage II multiple myeloma, a 78-year-old female patient was still receiving daratumumab plus lenalidomide maintenance and presented with mild fatigue during a routine follow-up.

Rapid responses and tolerable safety was shown with minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

CARTITUDE-1 update shows continued deep and durable response with iltacabtagene autoleucel in patients with heavily pretreated multiple myeloma.

Thomas G. Martin, MD, discusses the use of anti-CD38 antibodies in patients with multiple myeloma.

During a recent tweet chat with Alexander M. Lesokhin, MD, a hematologic oncologist with Memorial Sloan Kettering Cancer Center, joined Targeted Oncology to discuss the case of a 72-year-old White man with newly-diagnosed multiple myeloma.

At a live virtual event, David H. Vesole, MD, PhD, explained to other clinicians the use of daratumumab in the treatment of patients with newly diagnosed multiple myeloma who are either eligible or ineligible for autologous stem cell transplant.

During a Targeted Oncology Case-Based Roundtable event, Noa Biran, MD, discussed the case of a 51-year-old man with newly-diagnosed multiple myeloma.

The FDA has granted a fast track designation to ALLO-605, a next-generation allogeneic CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma.

During a Targeted Oncology Case-Based Roundtable event, Natalie S. Callander, MD, discussed the case of a 78-year-old patients with multiple myeloma.

Joseph Mikhael, MD, discussed the case of a 51-year-old patients with multiple myeloma.

Two years after being diagnosed with multiple myeloma and treated with the Dara-Rd regimen as induction therapy, a 78-year-old patient presented with mild fatigue during routine follow-up. James E. Hoffman, MD, discussed the case with a group of peers.

In a rountable Targeted Oncology talk, Sikander Ailawadhi, MD, leads a discussion on whether MRD affects multiple myeloma treatment decisions. He is joined by Ricardo Parrondo, MD Jeffrey Bubis, DO, Mathew Luke, MD, Sushma Simha Nakka, MD, and Thomas Cartwright, MD.

A warning from the FDA highlights that an increased rate of death has been observed in patients with multiple myeloma who are undergoing treatment with the FDA-approved agent melphalan flufenamide in combination with dexamethasone in the phase 2 OCEAN clinical trial.